NASDAQ:MDXG MiMedx Group Q2 2026 Earnings Report $4.36 +0.10 (+2.35%) Closing price 04:00 PM EasternExtended Trading$4.36 +0.00 (+0.11%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast MiMedx Group EPS ResultsActual EPSN/AConsensus EPS -$0.05Beat/MissN/AOne Year Ago EPSN/AMiMedx Group Revenue ResultsActual RevenueN/AExpected Revenue$63.46 millionBeat/MissN/AYoY Revenue GrowthN/AMiMedx Group Announcement DetailsQuarterQ2 2026Date7/29/2026TimeAfter Market ClosesConference Call DateWednesday, July 29, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile MiMedx Group Earnings HeadlinesEarnings To Watch: MiMedx Group Inc (MDXG) Q2 2026 -- GF Value Sees 35% UpsideJuly 28 at 11:10 AM | finance.yahoo.comMiMedx Group, Inc (NASDAQ:MDXG) Receives Average Rating of "Moderate Buy" from AnalystsJuly 28 at 2:58 AM | americanbankingnews.comTrump is positioned. Elon lights the fuse.Earlier this year, the Trump-backed World Liberty Trust applied for a federal banking charter. Now, new reports suggest approval could be coming much sooner than most investors expected. According to recent reports, approval now appears increasingly likely, which would allow a federally regulated crypto bank with authority to issue, redeem, and custody their stablecoin… which has already hit $3.4 billion in circulation. History shows us what happens when that kind of money floods into crypto. Bitcoin runs, and altcoins detonate. There's one coin sitting at the center of this ecosystem. It plays the same infrastructure role that Uniswap and PancakeSwap played in their early days… but for a system being turbocharged by Trump administration policy.July 28 at 1:00 AM | Crypto 101 Media (Ad)MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29July 20, 2026 | globenewswire.comLake Street Sticks to Their Buy Rating for MiMedx Group (MDXG)July 13, 2026 | theglobeandmail.comMiMedx Group (MDXG) Stock Faces Mixed Analyst Target Changes After Guidance CutJune 20, 2026 | finance.yahoo.comSee More MiMedx Group Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MiMedx Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MiMedx Group and other key companies, straight to your email. Email Address About MiMedx GroupMiMedx Group (NASDAQ:MDXG). is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety. MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair. The company also supplies specialized bioimplants for orthopedic and spine procedures, supporting soft-tissue repair through its PURION® Plus technology platform. These products are used by wound care centers, hospitals, long-term care facilities and physician offices. Headquartered in Marietta, Georgia, MiMedx serves a primarily U.S. customer base, with a growing international presence through distributors and strategic partnerships in Europe, Asia and Latin America. The company’s direct sales force works alongside a network of third-party distributors to educate clinicians on the clinical and economic benefits of its regenerative therapies. MiMedx continues to invest in clinical research and educational programs to expand awareness of placental-derived tissue allografts across multiple therapeutic areas. Founded in 2008, MiMedx has grown from a niche tissue processor to an established player in the regenerative medicine sector. Over its history, the company has received approvals from the U.S. Food and Drug Administration for tissue donor eligibility and manufacturing practices governed by FDA and American Association of Tissue Banks (AATB) standards. Leadership includes experienced professionals in biotechnology and medical device commercialization, supported by a board with backgrounds in healthcare investment and corporate governance.View MiMedx Group ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles These 3 Stocks Have Soared in 2026—Can They Keep Climbing?Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy StoryRambus: Another AI Phoenix Ready to Rise From the Ashes of CorrectionAmkor Sells Off After Earnings—Why Weak Guidance Isn't the Real StoryWestern Digital’s Earnings Will Test Whether Its AI Rally Has More RoomIs the Market Mispricing ServiceNow's AI Future?Whirlpool’s Report May Show How Frozen the Housing Market Really Is Upcoming Earnings Agnico Eagle Mines (7/29/2026)General Dynamics (7/29/2026)L3Harris Technologies (7/29/2026)Automatic Data Processing (7/29/2026)Amphenol (7/29/2026)ARM (7/29/2026)Fortinet (7/29/2026)Lam Research (7/29/2026)Meta Platforms (7/29/2026)Microsoft (7/29/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
